drugset / Trial / NCT02266875

Nebulized Hypertonic Saline for Inpatient Use in COPD

NCT02266875

Phase 4 Completed 70 enrolled OhioHealth
RandomizedParallel-groupSingle-blindTreatment

Summary

A comparison of albuterol treatments using hypertonic saline (3%) versus standard saline (0.9%) in patients with admitted patients COPD in regard to Modified Borg Dyspnea scale scores after 4 treatments within 24 hours.

Timeline

Start
2014-10
Primary completion
2017-01-30
Completion
2017-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Hypertonic saline Unknown 3 % Other